Tyra Biosciences (NASDAQ:TYRA) Director Buys $20,003.76 in Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Rehan Verjee bought 972 shares of the company’s stock in a transaction dated Wednesday, September 9th. The shares were acquired at an average price of $20.58 per share, for a total transaction of $20,003.76. Following the completion of the transaction, the director directly owned 972 shares in the company, valued at approximately $20,003.76. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

Tyra Biosciences Price Performance

NASDAQ TYRA traded down $1.53 during trading hours on Friday, reaching $22.01. The company’s stock had a trading volume of 1,548,623 shares, compared to its average volume of 916,127. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -9.17 and a beta of 0.73. Tyra Biosciences, Inc. has a 1-year low of $11.82 and a 1-year high of $40.65. The company’s 50-day moving average is $28.56 and its two-hundred day moving average is $31.91.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Equities analysts forecast that Tyra Biosciences, Inc. will post -2.74 EPS for the current fiscal year.

Tyra Biosciences News Summary

Here are the key news stories impacting Tyra Biosciences this week:

• Positive Sentiment: Tyra reported initial results from the Phase II SURF302 trial of oral dabogratinib. Coverage characterized the data as supportive of continued development in FGFR3-driven NMIBC, providing a potential clinical catalyst. Tyra announces initial data from Phase II SURF302 trial of dabogratinib Tyra Biosciences Phase II SURF302 results support LG IR NMIBC with dabogratinib
• Positive Sentiment: Wedbush reaffirmed its “Outperform” rating and maintained a $53 price target, while HC Wainwright kept a “Buy” rating and set a $30 target. These targets imply substantial upside and indicate that analysts still see value in Tyra’s pipeline despite the data reaction.
• Neutral Sentiment: A reported September short-interest figure of zero shares and a zero-day short-interest ratio provides no meaningful evidence of short-covering or increasing bearish positioning; the data also appears inconsistent with the reported trading activity.
• Negative Sentiment: Investors appeared disappointed with the bladder-cancer response data, with multiple reports describing the results as below expectations and the shares declining sharply after the Phase II update. The concern is that dabogratinib’s efficacy may not establish a sufficiently strong competitive position in NMIBC. Tyra shares slip as bladder cancer responses fall short of investor expectations
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Tyra investors. Such investigations can add reputational and legal overhang, although the announcement does not establish wrongdoing. Pomerantz investor alert

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TYRA. Jupiter Topco LLC purchased a new position in Tyra Biosciences during the second quarter worth approximately $139,161,000. Janus Henderson Group PLC grew its holdings in Tyra Biosciences by 32.5% in the 1st quarter. Janus Henderson Group PLC now owns 3,890,589 shares of the company’s stock valued at $148,867,000 after buying an additional 955,147 shares in the last quarter. Commodore Capital LP increased its stake in shares of Tyra Biosciences by 226.3% in the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock worth $29,667,000 after acquiring an additional 2,150,000 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Tyra Biosciences during the 2nd quarter valued at about $96,841,000. Finally, Farallon Capital Management LLC grew its holdings in shares of Tyra Biosciences by 80.7% in the fourth quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock valued at $54,337,000 after purchasing an additional 923,000 shares during the period. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently commented on TYRA. HC Wainwright cut their price target on shares of Tyra Biosciences from $45.00 to $30.00 and set a “buy” rating for the company in a report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Tyra Biosciences in a research report on Thursday. Jefferies Financial Group reissued a “buy” rating and set a $42.00 target price on shares of Tyra Biosciences in a research note on Wednesday, August 5th. JonesTrading began coverage on Tyra Biosciences in a report on Wednesday, June 17th. They set a “buy” rating and a $56.00 target price for the company. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $56.00 price target on shares of Tyra Biosciences in a research note on Tuesday. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $47.88.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.